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Abstract
Background: Extracorporeal membrane oxygenation (ECMO) is performed as an acceptable life-saving bridging
procedure in patients with severe acute respiratory distress syndrome (ARDS).To patients with avian influenza A
(H7N9)-associated ARDS, ECMO could be adopted as a feasible therapeutic solution. We present our successful
experience with ECMO utilized in a respiratory failure patient with H7N9 infection.
Case presentation: A 44 years-old female with H7N9-induced ARDS was admitted to intensive care unit (ICU)
and was treated with veno-venous ECMO for six days, antiviral therapy, prolonged corticosteroid infusion and
other therapies. She suffered significant hemorrhage requiring transfusion of platelets and multidrug-resistant
Acinetobacter Baumannii infection during ECMO support. Bleeding and infection almost killed the patient's life.
Fortunately, she was alive at last and completly recovered after 38 days of ICU stay.
Conclusions: ECMO was effective in this H7N9 patient with a fatal respiratory failure. Mechanical circulatory support
was the only chance for our patient with H7N9-associated ARDS to survive until respiratory function recovery. Early
detection and rapid response are essential to these serious ECMO-associated complications such as hemorrhage,
thrombosis and infection.
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Background
Acute respiratory distress syndrome (ARDS) is a serious
hypoxaemia and progressive dyspnea condition which is
caused by various direct or indirect factors leading to
the development of acute lung injury. Although medical
technology is more and more advanced and modern
medicine for ARDS has been further systematic in patho-
logical physiology, diagnosis and treatment scheme,
mortality rate due to ARDS is still high [1]. The study
found that fatality rate of patients with severe ARDS was
as high as 62% [2]. Extracorporeal membrane oxygen-
ation (ECMO) is a feasible life-saving support therapy
for patients with severe ARDS that is refractory to con-
ventional mechanical ventilation (MV) [3]. Originally
applied to support the respiratory function of pediatric
patients with good results [4], the use of ECMO has
been progressively extended to adult population [5].
Key factors for the indication of ECMO are represented
by prognosis of the underlying disease, timing, quality
of life of survivors and the possibility of being lung
transplant candidate [6]. Main ventilation strategy of
ECMO is to allow lungs of patients to rest and main-
tain theiropening, in order to get opportunity for
treatment of lung disease [7].
Occurrence of ARDS in patients with H7N9 infection
is associated to an extremely high mortality especially
before the introduction of effective antiviral treatment.
We present a clinical case of the successful use of
ECMO in a patient with H7N9-associated ARDS.
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Case presentation
The patient who had previously been exposed to poultry
was a 44 years-old female that had avian Influenza
A(H7N9) infection and presented with ARDS. After
15 days of flu-like respiratory symptoms and fever, the
patient developed severe respiratory distress and was
admitted to the emergency ward of local hospital. Two
days after the beginning of treatment with antibiotic, the
patient developed mild ARDS.That was initially treated
with non-invasive mechanical ventilation (NIV) in the
Intensive Care Unit (ICU) of superior hospital. Later,
ARDS evolved to the severe stage [8] and a significant
septic shock occurred. For this reason, three days after the
onset of respiratory failure, the patient received endo-
tracheal intubation and mechanical ventilation(MV).The
patient was referred to ECMO center of our hospital in
March 13, 2016 since conventional protective MV did not
improve the patient's condition..Severe ARDS (PaO2/
FiO2 = 46 mmHg) due to pneumonia caused by avian in-
fluenza A(H7N9) virus was diagnosed since the bronchial
lavage fluid (BLF) and pharynx swab were positive for
H7N9-RNA. Chest X-ray and CT scan showed diffuse and
bilateral pulmonary real change opacities (Fig. 1).
Upon arrival at the referral ECMO center, sepsis,
septic shock, acidosis and so forth, were treated and
veno-venous ECMO (VV-ECMO) was initiated (18 F
cannula was inserted into right jugular vein and right
femoral vein, respectively). The by-pass was established
with a blood flow of 4.13 L/min and sweep gas of 4 L/
min. This strategy offered the advantage to rest the lung
and minimize the risk of ventilator-induced lung injury
[9]. Details of antiviral therapy, steroid therapy, antibioti-
c,antifungal treatments and so on are shown in Table 1.
With the application of ECMO, the patient's blood gas
analysis results gradually improved (Table 2). Chest radi-
ography was taken every day. In the first radiograph
(Fig. 1), opacities and consolidation of almost the entire
left lung were demonstrated as “white lung”. However,
the opacities and consolidation disappeared gradually
(Fig. 1) when the infection was controlled, and the num-
ber of white cells returned to normal too.
Treatment with ECMO was maintained for 6 days and
stopped due to severe thrombocytopenia because heparin
must be applied when starting ECMO. Subcutaneous
hemorrhage occurred in fingers and left thigh of the pa-
tient. Bloody liquid was sucked out from bronchi. Platelet
antibodies were detected in blood and platelet transfusion
was ineffective. Fortunately, platelets gradually returned to
normal after the withdrawal of ECMO (Fig. 1). At the
same time, multidrug-resistant Acinetobacter Baumannii
infection was found in BLF, sputum and blood. It was for-
tunate that infection and thrombocytopenia were found in
time and gradually cured. On April 9, the patient was
successfully extubated and ventilated with non-invasive
ventilation (NIV) by face-mask. After 11 days, the patient
was discharged to a step down ICU and then at home.
After more than eight months of follow-up, the pharynx
swab H7N9-RNA remained negative and she was alive
finally with a good physical condition.
Discussion
Favorable outcomes in severe ARDS have been reported
with ECMO use during the 2009 H1N1 influenza pan-
demic, which led to increased interest and use of ECMO
for refractory respiratory failure. VV-ECMO can supply
sufficient pulmonary support when gas exchange is
Fig. 1 Chest X-Ray(Bedside)and computer tomography scans(No PEEP). MV mechanical ventilation,VV-ECMO veno-venous extracorporeal membrane
oxygenation. SaO2 Arterial Oxygen Saturation(%,NV > 95%)PLT platelet(×10
9/L)
Nie et al. BMC Pulmonary Medicine  (2017) 17:38 Page 2 of 5
severely compromised and presents an ultimate option
in problematic cases. However, indications for VV-
ECMO are not unequivocal and it is highly invasive,
presenting several specific problems and intellectual
concepts that require understanding in caring for these
patients. Since VV-ECMO is highly invasive and associ-
ated with numerous potential complications, such as
hemorrhage, thrombosis and infection, its use should
only be considered in patients with a high probability of
death with conventional treatment.
In fact, H7N9-associated ARDS carries a high mortality
rate. However, the care of patients with H7N9 infection
has advanced since the introduction of ECMO, with in-
creased life quality and decreased mortality. We performed
a retrospective observational analysis of our experience
with ECMO support for H7N9-associated ARDS. In this
report, ECMO is a crucial extracorporeal life support in
the H7N9 infection patient with severe ARDS.
The features of severe H7N9 avian flu patients are viral
infections, dyspnea, respiratory failure and ARDS, it final
developed to multiple organ failure and life-threatening.
Therefore, in addition to antiviral therapy(oseltamivir),
anti- multiple bacterial infections (application of antibi-
otics and anti-fungal drugs), glucocorticoid (methylpred-
nisolone) and the symptomatic treatment, the timely and
effective respiratory support is particularly important in
treatment of severe avian flu patients.
Our patient has entered a stage of ARDS when she
was hospitalized. Since mechanical ventilation by tra-
cheal intubation could not improve patient with hypoxia,
soon organ failure must occur in brain, heart, liver, kid-
neys and other vital organs of high oxygen demand.
Emergency VV-ECMO partial instead of lung ventilation
and oxygenation rapidly improved oxygen supplement of
Table 1 Main clinical characteristics of patient
Clinical characteristics




From March 13th to March 29th:positive
Acinetobacter Baumannii From March 17 to March 25:positive
Respiratory support
(outer court)
Time from symptoms onset to NIV (15 days);
Time from NIV to MV initiation (1 day);




March 13 to 19:VV-ECMO duration
March 13 to April 6:MV
April 6 to 9:high flow oxygen through
trachea cannula,oxygen flow rate:50 ~ 55
L/min
April 9 to 14:high flow oxygen through
face mask,oxygen flow rate:35 ~ 40 L/min
April 14 to 17:administering oxygen
inhalation through nasal catheter,oxygen
flow rate:2-6 L/min
April 17 to 20:stop oxygen inhalation
Antiviral therapy March 13 to April 1:Oseltamivir 150 mg,Bid
Anti infection treatments March 13 to April 16:Tienam 1.0
g,Tid;Tigecycline 50 mg,Bid;Moxifloxacin
400 mg,Qd.etc. Adjust medication
according to the results of culture and
drug sensitivity.
Antifungal therapy March 13 to April 11:Micafungin 50 mg,Qd.
steroid therapy March 13 to April 11:methylprednisolon
80 mg,Bid,gradually reduced dosage.
Table 2 Ventilator and ECMO parameters
Variable March 13(no ECMO) at admission March 14 ECMO(2nd day) March 19 ECMO((7th day) March 21 stop ECMO(3rd day)
vital sign T:36.7,HR:129, BP:74/36 T:35.8,HR:76, BP:119/81 T:36.5,HR:77, BP:122/79 T:36.9,HR:68, BP:132/67
MV mode SIMV PCV-SIMV SIMV SIMV
PEEP 18 8 12 18
FiO2 100% 40% 60% 70%
f 20 10 12 16
SaO2 69% ~ 83% 98% 99% 97%
Blood Flow – 3.46 L/min 3.00 L/min –
Sweep Flow – 2.50 L/min 3.00 L/min –
PH 7.274 7.315 7.440 7.468
PaO2 6.92 13.41 18.00 27.20
PaCO2 5.69 4.92 6.06 6.50
T temperature(°C),HR heart rate(bpm),BP blood pressure(mmHg),MV mechanical ventilation,SIMV synchronized intermittent mandatory ventilation,PCV Pressure
Control Ventilation,PEEP Positive End Expiratory Pressure (cmH2O),FiO2 Fraction of inspired oxygen(%),F mechanical ventilation frequency(bpm),SaO2 Arterial
Oxygen Saturation(%,NV > 95%),PH value(7.35-7.45),PaO2 Partial pressure of oxygen in arterial blood (kPa,NV:10.66-13.33),PaCO2 Partial pressure of carbon dioxide
in arterial blood (kPa,NV:4.65-5.98)
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the body organs. It avoided the occurrence of multiple
organ failure, decreased support of respiratory machine,
reduced ventilator-associated lung injury, for lungs to
get adequate rest, thus won time for treatment of the
primary disease.
Evidence supporting ECMO as life saving treatment for
adults with respiratory failure are growing [10]. However,
ECMO is a costly intervention that may carry the risk of
futility and serious side effects such as major bleeding and
infection. During ECMO support, as heparin must be ap-
plied at the same time, so thrombocytopenia and coagu-
lopathy inevitably arise in patients. ECMO was started at
13:20 on March 13 for our patient, dramatic decrease in
platelets (PLT 48x109/L) was found on March 15. Skin ec-
chymosis was appeared in the groin where catheters were
placed on March 19, subcutaneous hemorrhage occurred
in fingers and left thigh of the patient, platelet had fallen
to 21 × 109/L. But more worrying was that bloody liquid
was sucked out from bronchi and platelet transfusion did
not work. Through discussion with experts, ECMO was
withdrawn at 17:05 on March 19, and thrombopoietic
treatment and platelet monitoring were continued, finally,
the platelet returned to the normal range on April 3. In-
fection is another side effect of the application of ECMO.
Four days after hospitalization, BLF, sputum and blood
stream infection with multidrug-resistant Acinetobacter
Baumannii occurred in our patient, which could lead to
septic shock and death. Fortunately, we discovered and
prevented the progress of infection in time.
Under these circumstances, indication and selection cri-
teria need to be better defined.In our report, ECMO was
used in severe, life threatening respiratory failure caused
by a curable bird flu disease. Extracorporeal Life Support
Organization (ELSO) guide-lines suggest ECMO when the
risk for mortality is at least 50% (as identified by PaO2/
FiO2 < 150 and or Murray score of 2–3) [11]. In this case,
VV-ECMO was performed because PaO2/FiO2 ratio of
the patient was only 46 mmHg. Fact proved that VV-
ECMO for H7N9-associated respiratory failure gave a
good result.
Conclusions
ECMO was a feasible salvage modality in this H7N9
patient with an fatal respiratory failure.ECMO is not the
only factor to improve the condition of patient, the
combined effect of hormone and antiviral therapy, anti-
shock therapy helps patient to survive. It was also im-
portant to discover in time and rapid response serious
ECMO-associated complications. Our patient was cured
and went back to her previous quality of life at last,
thanks to ECMO giving her time to get treatment. This
case suggests that a multidisciplinary team, involving
critical care and infectious diseases experts, is very crit-
ical to define whether ECMO is an adequate therapeutic
option also in patients with severe pulmonary infectious
diseases. We recommend treatment with ECMO as early
as possible, but more clinical evidence is required to
support this view. Further studies are needed to under-
stand how to best utilize and optimize ECMO therapy in
patients with ARDS. In short, our successful treatment
of patients with severe H7N9 avian flu should be cred-
ited to application of ECMO and important ventilation
adjustment according to patient's condition. Retrospect-
ive analysis of comprehensive treatment of this patient
provided a reliable reference to treatment of ARDS and
severe pneumonia.
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